NASDAQ$HOLX
Hologic Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Hologic delivered excellent results, significantly exceeding expectations, and topping off another tremendous year.
Hologic's Q4 2022 revenue reached $953.3 million, a decrease of 27.6% compared to the previous year, driven by lower COVID-19 assay sales and supply chain challenges. GAAP diluted EPS was $0.47, while Non-GAAP diluted EPS was $0.82, both exceeding expectations. The company anticipates strong growth in core businesses for fiscal year 2023.
- Revenue of $953.3 million decreased (27.6%) for the quarter, or (25.6%) in constant currency, primarily driven by lower sales of COVID-19 assays and supply chain challenges related to semiconductor chips in our Breast Health business compared to the prior year period.
- Diagnostics revenue decreased (37.8%), or (35.6%) in constant currency, primarily driven by lower sales of COVID-19 assays compared to the prior year period. Excluding COVID-19 revenues, Diagnostics revenue grew 11.1% on an organic, constant currency basis.
- Molecular Diagnostics revenue declined (43.2%), or (41.3%) in constant currency, primarily driven by lower sales of COVID-19 assays compared to the prior year period. Excluding COVID-19 revenues, Molecular Diagnostics revenue grew 17.2% on an organic, constant currency basis.
- Breast Health revenue, as expected, declined (17.7%), or (16.0%) in constant currency, primarily due to lower gantry revenue resulting from semiconductor chip shortages.
Headline financials
Revenue & EPS history
Hologic · Revenue · Quarterly
$953M
Revenue by segment
Hologic · $1.2B total across 3 segments · Q4 2022
- Diagnostics$521M-37.8%43.5%
- Molecular Diagnostics$400M-43.2%33.5%
- Breast Health$275M-17.7%23.0%
Forward guidance
Hologic provided financial guidance for Q1 and full year 2023, anticipating continued strength in base diagnostics and surgical businesses, along with a strong rebound in the breast health business. The guidance assumes low double-digit constant currency organic revenue growth ex. COVID-19 in each division for full-year fiscal 2023.
Tailwinds
- Continued strength in base Diagnostics business
- Continued strength in Surgical businesses
- Strong rebound in Breast Health business over the course of the year
- Low double-digit constant currency organic revenue growth ex. COVID-19 in each division for full-year fiscal 2023.
- Full year non-GAAP tax rate of approximately 19.0%
Headwinds
- Q1 2023 Revenue $940 - $990 (36.1%) to (32.7%)
- Q1 2023 GAAP EPS $0.60 - $0.70 (69.2%) to (64.1%)
- Q1 2023 Non-GAAP EPS $0.80 - $0.90 (63.1%) to (58.5%)
- Fiscal 2023 Revenue $3,700 - $3,900 (23.9%) to (19.8%)
- Fiscal 2023 GAAP EPS $2.51 - $2.81 (51.1%) to (45.2%)
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2022
-0.5%
Avg return
Earnings day
+0.2%
Avg return
5 days after
-0.1%
Avg return
30 days after
49%
35 / 72 earnings
Positive
+12.3%
Q3 2020
Best reaction
-11.4%
Q2 2012
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | — | — | — | |
| Q1 2026 | +0.0% | -0.6% | +0.7% | |
| Q4 2025 | +0.1% | +0.1% | +0.9% | |
| Q3 2025 | +2.8% | +4.4% | +3.3% | |
| Q2 2025 | -5.6% | -3.2% | +8.5% | |
| Q1 2025 | -10.1% | -11.4% | -11.3% | |
| Q4 2024 | -4.3% | -4.3% | -6.6% | |
| Q3 2024 | +4.9% | +6.4% | +2.2% | |
| Q2 2024 | +0.3% | -0.2% | -3.3% | |
| Q1 2024 | -2.7% | -0.4% | -1.1% | |
| Q4 2023 | +5.7% | +5.4% | +0.1% | |
| Q3 2023 | -5.1% | -5.9% | -5.4% | |
| Q2 2023 | -2.4% | -2.6% | -8.3% | |
| Q1 2023 | +3.8% | +3.6% | -1.1% | |
| Q4 2022 | +10.8% | +12.4% | +13.8% | |
| Q3 2022 | +1.0% | +1.3% | -3.4% | |
| Q2 2022 | +1.2% | +3.4% | +9.8% | |
| Q1 2022 | +4.0% | +3.8% | +2.4% | |
| Q4 2021 | -3.3% | -5.9% | -0.3% | |
| Q3 2021 | +2.3% | +5.0% | +9.7% | |
| Q2 2021 | -9.1% | -9.9% | -13.4% | |
| Q1 2021 | +1.7% | +11.2% | -3.3% | |
| Q4 2020 | +6.6% | -5.0% | +1.7% | |
| Q3 2020 | +12.3% | +14.8% | -2.8% | |
| Q2 2020 | +2.9% | +2.6% | +8.9% | |
| Q1 2020 | -0.7% | -1.8% | -13.7% | |
| Q4 2019 | -4.0% | +8.8% | +10.3% | |
| Q3 2019 | -1.3% | -6.5% | -4.1% | |
| Q2 2019 | -0.1% | +0.7% | -5.1% | |
| Q1 2019 | +0.6% | -0.5% | +8.6% | |
| Q4 2018 | +4.9% | +1.2% | +3.7% | |
| Q3 2018 | -3.5% | -1.9% | -7.5% | |
| Q2 2018 | -6.9% | -6.8% | -3.9% | |
| Q1 2018 | -6.7% | -6.6% | -2.2% | |
| Q4 2017 | +0.4% | +2.9% | +8.1% | |
| Q3 2017 | -9.3% | -11.3% | -12.5% | |
| Q2 2017 | -4.3% | -5.1% | -2.0% | |
| Q1 2017 | -2.6% | -2.9% | +1.8% | |
| Q4 2016 | +4.3% | +8.5% | +6.3% | |
| Q3 2016 | +3.9% | +5.8% | +5.3% | |
| Q2 2016 | -10.0% | — | — | |
| Q1 2016 | -9.2% | — | — | |
| Q4 2015 | +0.6% | — | — | |
| Q3 2015 | +8.6% | — | — | |
| Q2 2015 | +2.1% | — | — | |
| Q1 2015 | +5.1% | — | — | |
| Q4 2014 | -1.7% | — | — | |
| Q3 2014 | +2.1% | — | — | |
| Q2 2014 | +8.1% | — | — | |
| Q1 2014 | -5.9% | — | — | |
| Q4 2013 | -6.9% | — | — | |
| Q3 2013 | -0.2% | — | — | |
| Q2 2013 | +0.1% | — | — | |
| Q1 2013 | -4.1% | — | — | |
| Q4 2012 | -0.3% | — | — | |
| Q3 2012 | -0.4% | — | — | |
| Q2 2012 | -11.4% | — | — | |
| Q1 2012 | +5.2% | — | — | |
| Q4 2011 | -4.0% | — | — | |
| Q3 2011 | -3.9% | — | — | |
| Q2 2011 | -0.6% | — | — | |
| Q1 2011 | +0.0% | — | — | |
| Q4 2010 | +1.2% | — | — | |
| Q3 2010 | +1.2% | — | — | |
| Q2 2010 | -2.6% | — | — | |
| Q1 2009 | -2.8% | — | — | |
| Q1 2010 | -1.1% | — | — | |
| Q2 2009 | +2.9% | — | — | |
| Q4 2007 | +2.9% | — | — | |
| Q4 2009 | +2.9% | — | — | |
| Q3 2009 | -3.0% | — | — | |
| Q3 2008 | -3.0% | — | — | |
| Q4 2008 | -3.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro